Tag: spinal cord stimulation
Medtronic announces trial data on closed-loop and DTM SCS therapies at...
At this year’s North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas, USA), Medtronic announced new data from two clinical trials demonstrating...
Nevro to highlight 25 scientific abstracts on spinal cord stimulation at...
Nevro Corporation has announced a series of data presentations supporting the use of the company's high-frequency (HFX) 10kHz spinal cord stimulation (SCS) therapy for...
Washington state “poised” to extend spinal cord stimulation coverage following straw...
As per a recent statement from the North American Neuromodulation Society (NANS), the US state of Washington may be about to extend its insurance...
Nalu announces positive results from spinal cord stimulation nPower US clinical...
Nalu Medical has announced the publication of the spinal cord stimulation (SCS) nPower US clinical study in the Pain Physician Journal, reporting on clinical outcomes...
SpineX announces new report on SCS improving bladder function in stroke...
SpineX has reported in a press release that a publication titled, “A pilot study of the effect of transcutaneous spinal cord stimulation on micturition-related...
Medical necessity “should drive all remote monitoring decisions” in SCS, expert...
The principle of medical necessity “should drive all remote monitoring decisions” relating to spinal cord stimulation (SCS) technologies, according to recommendations recently published in...
Biotronik announces new data supporting effectiveness of RESONANCE multiphase stimulation paradigm
Biotronik Neuro has announced that results from the BENEFIT-02 trial—the “first of its kind” to clinically evaluate a multiphase stimulation paradigm—support the effectiveness of...
NANS leads multi-society response to “methodologically flawed” SCS re-review in Washington...
The North American Neuromodulation Society (NANS) has led a multi-society response to the Washington State Health Care Authority (WSHCA) following its review of the...
Onward announces first-in-human implant of ARC-IM stimulator with wireless BCI device
Onward Medical has today announced the successful first-in-human implant of its ARC-IM stimulator intended to restore upper-extremity function after spinal cord injury (SCI). The...
Nevro announces new data demonstrating health economic benefits of 10kHz SCS...
Nevro Corporation has announced the publication of new data validating the health economic benefits of 10kHz therapy, the company’s proprietary, high-frequency spinal cord stimulation...
Medtronic receives CE-mark approval for Inceptiv closed-loop SCS to treat chronic...
Medtronic has received CE-mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator in the treatment of chronic pain.
Inceptiv is the first Medtronic spinal...
Education and collaboration key to continued advancement of painful diabetic neuropathy...
The neuromodulation space has proliferated significantly over the past few years, and one area in which this is most notable is with the expansion...
Cochrane Library urged to retract and revise recent SCS review over...
Pain physicians have urged the Cochrane Library to retract and revise a recent review of spinal cord stimulation (SCS) in the treatment of low...
Brain-computer interface plus SCS therapy enables thought-controlled walking after spinal cord...
Onward Medical has announced a recent publication in Nature showing that a wireless brain-computer interface (BCI) can use patients’ thoughts to modulate ARC therapy....
The new standard for SCS therapy—neural activation measurement, targeting and maintenance
Jason Pope (Santa Rosa, USA) discusses closed-loop spinal cord stimulation (SCS) and its potential to provide sustained, holistic outcomes for chronic pain patients. In...
Biotronik announces US FDA approval of Prospera spinal cord stimulation system
Biotronik has announced US Food and Drug Administration (FDA) approval for Prospera—a new spinal cord stimulation (SCS) system. The system features RESONANCE, which the...
Review concludes SCS benefits do not outweigh associated risks and costs...
A recently published Cochrane review has concluded that the clinical benefits of spinal cord stimulation (SCS) do not outweigh the risks and costs associated...
NeuroOne completes initial animal implant of thin-film paddle lead for spinal...
NeuroOne Medical Technologies has announced the successful completion of an initial animal implant of its novel, thin-film paddle leads for spinal cord stimulation (SCS)....
Nevro announces full US market launch of HFX iQ spinal cord...
Nevro Corporation announced today that it has now initiated the full US market launch of its HFX iQ spinal cord stimulation (SCS) system, following...
Spinal cord stimulation found to “instantly improve” post-stroke arm and hand...
Spinal cord stimulation (SCS) therapy has been shown to trigger instant improvements in arm and hand mobility, enabling people affected by moderate-to-severe stroke to...
SCS therapies can play a role in cancer-related pain treatment despite...
Spinal cord stimulation (SCS) therapies targeting the dorsal column “may be considered” within the multimodal treatment plans typically required by cancer patients, but it...
FDA approves Abbott’s spinal cord stimulation system for those with painful...
Abbott has announced that the US Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral...
Abbott launches Eterna spinal cord stimulation system for the treatment of...
Abbott has announced US Food and Drug Administration (FDA) approval of its Eterna spinal cord stimulation (SCS) system—which the company describes as the world’s...
Saluda Medical initiates US commercialisation of the Evoke spinal cord stimulation...
Saluda Medical has announced plans for a limited commercial release of its Evoke spinal cord stimulation (SCS) system in the USA, with a full commercial...
Gimer Medical granted IDE approval for spinal cord stimulation system
Gimer Medical today announced that the company’s spinal cord stimulation (SCS) system was granted conditional investigational device exemption (IDE) approval by US Food and...
Abbott gains US FDA approval for Proclaim Plus spinal cord stimulation...
Abbott has announced that the US Food and Drug Administration (FDA) has approved its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360...
Saluda Medical presents data on 24-month holistic response to spinal cord...
Saluda Medical has announced that Steven Falowski (Argires-Marotti Neurosurgical Associates of Lancaster, Lancaster, USA) recently presented late-breaking 24-month data from the company’s EVOKE study at...
High responder rates, substantial pain relief and no explants among key...
Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...
High-frequency SCS drives impactful outcomes for non-surgical refractory back pain patients
Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...
Saluda Medical raises US$125m to boost Evoke spinal cord stimulation offering
Saluda Medical has finalised US$125 million in equity financing, with the proceeds being used in part to operationalise and scale commercialisation of the company’s Evoke spinal...
Multiple-modality spinal cord stimulation demonstrates sustained improvement in chronic pain outcomes
A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...
Saluda Medical receives FDA approval for the Evoke spinal cord stimulation...
Saluda Medical has announced that it has received full approval from the US Food and Drug Administration (FDA) for the Evoke spinal cord stimulation (SCS)...
SCS for postlaminectomy syndrome associated with minor reductions in opioid use,...
Spinal cord stimulation (SCS) for postlaminectomy syndrome (PLS) is associated with small, clinically questionable opioid discontinuation and a lower rate of new opioid use...
Medtronic announces FDA approval of spinal cord stimulation therapy for treating...
Medtronic has received US Food and Drug Administration (FDA) approval of its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for the treatment of chronic...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
FDA grants StimuLux system breakthrough device designation
Wavegate Corporation has announced that the US Food and Drug Administration (FDA) has granted breakthrough device designation for its StimuLux optical reflectometry system for...
DTM spinal cord stimulation endurance therapy associated with meaningful pain relief...
Differential Target Multiplexed (DTM) spinal cord stimulation (SCS) endurance therapy provides meaningful pain relief according to three-month data from the DTM-LE trial—the findings of...
Current gaps and barriers in patient access to spinal cord stimulation
Maricela Schnur (St Luke’s Hospital, Duluth, USA) highlights a handful of socioeconomic disparities, racial differences, and psychological and psychiatric factors that currently present difficulties...
Proclaim XR spinal cord stimulation system gets expanded MRI compatibility boost
Abbott has announced that the US Food and Drug Administration (FDA) has approved new expanded magnetic resonance imaging (MRI) compatibility for its Proclaim XR spinal cord...
Passive recharge burst spinal cord stimulation provides sustainable improvements in pain...
Passive recharge burst spinal cord stimulation (B-SCS) can alleviate pain intensity, psychological distress, and improve physical function and health-related quality of life out to two years,...
High-frequency SCS takes the stage to relieve chronic pain from diabetic...
Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
NeoSpine first to offer spinal cord stimulation for treatment of painful...
NeoSpine is now offering spinal cord stimulation (SCS) procedures for the treatment of painful diabetic neuropathy (PDN) via its HFX system—a newly approved nondrug treatment...
Boston Scientific launches FAST—a new therapy for spinal cord stimulation
Boston Scientific has announced the European launch of FAST—a new fast-acting sub-perception therapy that the company says is clinically proven to demonstrate significant and...
Nevro announces FDA approval of high-frequency SCS therapy for painful diabetic...
Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system to treat chronic pain associated with painful diabetic...
New ultra-thin Inflatable spinal implants could help treat severe pain
A team of engineers and clinicians at the University of Cambridge (Cambridge, UK) have developed an ultra-thin, inflatable spinal device that can be used...
WaveWriter Alpha Spinal Cord Stimulator System wins Best Overall Medical Device...
The WaveWriter Alpha Spinal Cord Stimulator (SCS) System (Boston Scientific) has been named Best Overall Medical Device Solution at the fifth annual MedTech Breakthrough...
Medtronic launches spinal cord stimulation therapy mobile app
Medtronic has announced the launch of CareGuidePro, a new mobile application and web portal that serves as a virtual guide for patients throughout their...
Nevro receives US FDA approval for Senza Omnia spinal cord stimulation...
Nevro has received approval from the US Food and Drug Administration (FDA) for the Senza Omnia spinal cord stimulation system to treat chronic pain....
Nevro receives TGA approval for Senza II spinal cord stimulation system...
The Therapeutic Goods Administration (TGA) has granted approval to Nevro for its next-generation Senza II spinal cord stimulation system delivering the company’s proprietary HF10...
Immediate restoration of voluntary movement with epidural spinal cord stimulation in...
In a small cohort of patients, spinal cord stimulation has been shown to restore volitional movement in select patients with paraplegia, after intensive therapy....
Non-opioid alternative for chronic pain approved in Europe
A Conformité Européene (CE) Mark has been received by Medtronic for its neurostimulation platform Intellis for spinal cord stimulation (SCS) and peripheral nerve stimulation...
Todd Wetzel
As his term as NASS president comes to a close, Spinal News International caught up with Todd Wetzel to discuss his career to date,...
Flexible battery could revolutionise implanted devices
Experts at Queen’s University Belfast, Belfast, UK, have designed a flexible battery that could provide an alternative to the rigid batteries that usually power...
CE mark approval for Stimwave’s world-first fully percutaneous spinal cord stimulator...
CE mark approval has been granted for the world’s first percutaneous injectable anchor system, SandShark. The Stimwave system is used to fixate the company’s...
NASS’ allograft and spinal cord stimulation coverage recommendations open for public...
The president of the North American Spine Society (NASS), F Todd Wetzel (Philadelphia, USA), has announced the opening of the society’s 30-day public comment...
Man moves paralysed legs using spinal cord stimulation
Mayo Clinic (Rochester, USA) researchers have used electrical stimulation on the spinal cord and intense physical therapy to help a man intentionally move his...
Spinal cord stimulation reduces or stabilises opioid use among chronic pain...
New research has found spinal cord stimulation therapy can reduce or stabilise the use of opioids in patients battling chronic pain. Researchers examined opioid...
Most patients with chronic truck or limb pain experience “substantial” pain...
Twenty-four month data from a postmarket, clinical registry have found that most patients suffering from chronic pain of the trunk and/or limbs reported “substantial”...